What's Happening?
Biozen, LLC announced that it will present clinical validation data for its cuffless blood pressure technology at the American College of Cardiology (ACC) Scientific Sessions. The presentation will feature results from a study evaluating Biozen's BP1000
device, which uses proprietary pressure and optical sensing to measure blood pressure without a cuff. The study, conducted under the ISO 81060-2:2018 validation protocol, involved 264 participants and demonstrated the device's performance against the clinical gold standard. The presentation marks a significant milestone for Biozen's technology, which aims to provide a more convenient and accurate method for blood pressure monitoring.
Why It's Important?
Biozen's cuffless blood pressure technology represents a potential breakthrough in the field of digital health, offering a more user-friendly and accessible alternative to traditional cuff-based devices. This innovation could improve patient compliance and enable more frequent monitoring, leading to better management of hypertension and related conditions. The technology's ability to accurately measure blood pressure in diverse populations, including those with darker skin tones and obesity, addresses a critical gap in current monitoring systems. If successfully commercialized, Biozen's device could transform how blood pressure is monitored and managed in clinical and home settings.
